ADC Therapeutics SA ADCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
ADC Therapeutics Announces New Employee Inducement Grant
-
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
-
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
-
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
-
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
Trading Information
- Previous Close Price
- $1.29
- Day Range
- $1.23–1.29
- 52-Week Range
- $0.78–4.98
- Bid/Ask
- $1.21 / $1.30
- Shares Outstanding
- 127.19M
- Market Cap
- $158.99M
- Volume/Avg
- 635,107 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.26
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 193
- Website
- https://www.adctherapeutics.com
Valuation
|
Metric
|
ADCT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 2.26 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ADCT
|
|---|---|
Quick Ratio | 3.87 |
Current Ratio | 4.09 |
Interest Coverage | −1.80 |
Quick Ratio
ADCT
Profitability
|
Metric
|
ADCT
|
|---|---|
Return on Assets (Normalized) | −29.17% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ADCT
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|DHQq>kyc | LOCK|gjyg@ | $69B | |||
| Haleon PLC ADR
HLN
| LOCK|J<wBX^ | LOCK|jB | $43B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| LOCK|RQTHJH!@ | LOCK|mdhL% | $38B | |||
| Zoetis Inc Class A
ZTS
| LOCK|fk^mX^$ | LOCK|!@ | $32B | |||
| Viatris Inc
VTRS
| LOCK|G<dSw< | LOCK|<k | $19B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|W!& | LOCK|P#& | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|dl>X>#? | LOCK|!?H | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|M%!ZjW | LOCK|@k | $8B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|v%rV>T | LOCK|!NcqC | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|DC$Yh@W | LOCK|cL | $1B |
United States